ATE451935T1 - Behandlungsverfahren mit liganden- immunogenkonjugaten - Google Patents
Behandlungsverfahren mit liganden- immunogenkonjugatenInfo
- Publication number
- ATE451935T1 ATE451935T1 AT02789173T AT02789173T ATE451935T1 AT E451935 T1 ATE451935 T1 AT E451935T1 AT 02789173 T AT02789173 T AT 02789173T AT 02789173 T AT02789173 T AT 02789173T AT E451935 T1 ATE451935 T1 AT E451935T1
- Authority
- AT
- Austria
- Prior art keywords
- ligand
- pathogenic cells
- immunogen
- treatment methods
- population
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 102000002689 Toll-like receptor Human genes 0.000 abstract 1
- 108020000411 Toll-like receptor Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32579301P | 2001-09-28 | 2001-09-28 | |
| US32633201P | 2001-10-01 | 2001-10-01 | |
| US39165402P | 2002-06-26 | 2002-06-26 | |
| PCT/US2002/030546 WO2003028634A2 (en) | 2001-09-28 | 2002-09-26 | Method of treatment using ligand-immunogen conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE451935T1 true ATE451935T1 (de) | 2010-01-15 |
Family
ID=32738720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02789173T ATE451935T1 (de) | 2001-09-28 | 2002-09-26 | Behandlungsverfahren mit liganden- immunogenkonjugaten |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20030086900A1 (de) |
| EP (2) | EP2168598A1 (de) |
| JP (1) | JP2005523878A (de) |
| KR (1) | KR20040053136A (de) |
| AT (1) | ATE451935T1 (de) |
| CA (1) | CA2461877A1 (de) |
| DE (1) | DE60234782D1 (de) |
| DK (1) | DK1434603T3 (de) |
| ES (1) | ES2338305T3 (de) |
| WO (1) | WO2003028634A2 (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| SK288201B6 (sk) * | 2000-03-31 | 2014-06-03 | Purdue Research Foundation | Farmaceutický prostriedok |
| WO2002085908A1 (en) * | 2001-04-24 | 2002-10-31 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
| KR20040015234A (ko) * | 2001-05-02 | 2004-02-18 | 펄듀 리서치 파운데이션 | 대식세포 매개된 질환의 치료와 진단 |
| AU2002331366A1 (en) * | 2001-07-31 | 2003-02-17 | Paola Castagnoli | Dendritic cells and the uses thereof in screening cellular targets and potential drugs |
| EP1496934A4 (de) * | 2002-04-19 | 2006-08-02 | Endocyte Inc | Adjuvante verbesserte immunotherapie |
| DE60326833D1 (de) * | 2002-05-15 | 2009-05-07 | Endocyte Inc | Vitamin-mitomycin-konjugate |
| EP1592457B1 (de) | 2003-01-27 | 2012-07-25 | Endocyte, Inc. | Folat-vinblastin konjugat als arzneimittel |
| EP1599170B1 (de) * | 2003-02-21 | 2013-01-16 | Hasumi Llc (Dba Shukokai International) | Humanes lymphozyten-vakzineadjuvans |
| CA2524441C (en) * | 2003-05-06 | 2012-03-20 | Purdue Research Foundation | Treatment of lupus targeting the macrophages or the folate receptor |
| AU2004275876B2 (en) * | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
| CA2551189A1 (en) * | 2003-12-24 | 2005-07-07 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic agents and uses therefor |
| CA2555390C (en) * | 2004-02-19 | 2014-08-05 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral rna oligonucleotides |
| TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
| EP1753453A2 (de) * | 2004-06-08 | 2007-02-21 | Coley Pharmaceutical GmbH | Abasische oligonukleotide als trägerplattform für antigen- und immunstimulatorische agonisten und antagonisten |
| JP5149620B2 (ja) | 2004-07-23 | 2013-02-20 | エンドサイト，インコーポレイテッド | ２価リンカーおよびその結合体 |
| EP1863816B1 (de) * | 2005-03-16 | 2014-06-25 | Endocyte, Inc. | Synthese und aufreinigung von pteroinsäure und konjugaten davon |
| DE602006012816D1 (de) | 2005-03-30 | 2010-04-22 | Endocyte Inc | Tifizierung von zellulären folat vitamin rezeptoren |
| EP1904183B1 (de) | 2005-07-05 | 2014-10-15 | Purdue Research Foundation | Pharmazeutische Zusammensetzung zur Behandlung von Arthrose |
| CN103893779A (zh) * | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
| EP1948240A2 (de) * | 2005-08-19 | 2008-07-30 | Endocyte, Inc. | Liganden-konjugate von vinca-alkaloiden, analoga und derivaten |
| US8357671B2 (en) | 2005-11-10 | 2013-01-22 | James Paulson | High affinity Siglec ligands |
| US20070161546A1 (en) * | 2005-12-15 | 2007-07-12 | Colm King | Methods and compositions for treatment of cancer |
| US8168164B2 (en) | 2006-02-03 | 2012-05-01 | Purdue Research Foundation | Targeted conjugates and radiation |
| EP1991678B2 (de) * | 2006-02-15 | 2020-07-15 | Rechtsanwalt Thomas Beck | Zusammensetzungen und verfahren für oligonukleotidformulierungen |
| JP5869205B2 (ja) | 2007-02-07 | 2016-02-24 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | ポジトロン放射断層画像法 |
| WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| NZ599239A (en) * | 2007-03-14 | 2013-10-25 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins |
| US8961926B2 (en) * | 2007-05-25 | 2015-02-24 | Purdue Research Foundation | Method of imaging localized infections |
| JP5690589B2 (ja) | 2007-06-25 | 2015-03-25 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 親水性スペーサーリンカーを含有する結合体 |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| ES2768224T3 (es) | 2007-08-17 | 2020-06-22 | Purdue Research Foundation | Conjugados ligando-enlazador de unión a PSMA y métodos para su uso |
| JP2011500835A (ja) | 2007-10-25 | 2011-01-06 | エンドサイト，インコーポレイテッド | チューブリシン類および調製プロセス |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
| US9629918B2 (en) | 2012-02-29 | 2017-04-25 | Purdue Research Foundation | Folate receptor alpha binding ligands |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| JP2015536323A (ja) | 2012-10-16 | 2015-12-21 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 非天然アミノ酸を含む薬物送達結合体および使用方法 |
| CA2891476C (en) | 2012-11-15 | 2022-07-05 | Endocyte, Inc. | Drug delivery conjugates, and methods for treating diseases caused by psma expressing cells |
| ES2977715T3 (es) | 2013-10-18 | 2024-08-29 | Novartis Ag | Inhibidores marcados de antígeno prostático específico de membrana (psma), su uso como agentes formadores de imágenes y agentes farmacéuticos para el tratamiento de cáncer de próstata |
| BR112016010927A2 (pt) | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| WO2019204335A1 (en) | 2018-04-17 | 2019-10-24 | Endocyte, Inc. | Methods of treating cancer |
| CN114269346A (zh) * | 2019-07-08 | 2022-04-01 | 普渡研究基金会 | 用于治疗和预防纤维化疾病状态和癌症的化合物和方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2816110A (en) * | 1956-11-23 | 1957-12-10 | Merck & Co Inc | Methods for the production of substituted pteridines |
| US4314988A (en) * | 1979-10-31 | 1982-02-09 | Baker Instruments Corp. | Folic acid derivatives and process for preparation |
| US4713249A (en) * | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
| US4659655A (en) * | 1981-11-25 | 1987-04-21 | Bio-Response, Inc. | Method for isolating product-producing cells |
| US5140104A (en) * | 1982-03-09 | 1992-08-18 | Cytogen Corporation | Amine derivatives of folic acid analogs |
| IT1203672B (it) * | 1982-05-12 | 1989-02-15 | Harvard College | Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina |
| NL8401226A (nl) * | 1984-04-16 | 1985-11-18 | Univ Utrecht | Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie. |
| US5266333A (en) * | 1985-03-06 | 1993-11-30 | American Cyanamid Company | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone |
| US4681760A (en) * | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| NZ217821A (en) * | 1985-10-10 | 1989-07-27 | Biotech Australia Pty Ltd | Oral delivery system; complex of active agent and vitamin b12 or analogue thereof |
| US5117022A (en) * | 1985-10-18 | 1992-05-26 | The Board Of Regents, The University Of Texas System | Hydrophobic cis-platinum complexes efficiently incorporated into liposomes |
| JPS6479125A (en) * | 1986-08-13 | 1989-03-24 | Takeda Chemical Industries Ltd | Antitumor agent |
| US4971792A (en) * | 1987-03-27 | 1990-11-20 | The Wistar Institute | Monoclonal antibodies against glycolipid antigens |
| US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5583112A (en) * | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
| US4946945A (en) * | 1987-06-23 | 1990-08-07 | Allergy Immuno Technologies, Inc. | Immunotherapy agents for treatment of IgE mediated allergies |
| GB8803365D0 (en) * | 1988-02-13 | 1988-03-16 | Ciba Geigy Ag | Antiviral combination |
| WO1990009804A1 (en) * | 1989-02-24 | 1990-09-07 | The Regents Of The University Of California | Genetically engineered immunoglobulins |
| US5075287A (en) * | 1989-03-03 | 1991-12-24 | Nisshin Oil Mills, Inc. | Muramyl peptide derivatives and immunoregulating compositions containing them |
| US5688488A (en) * | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
| US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5217881A (en) * | 1989-04-25 | 1993-06-08 | Immunex Corporation | Hyperglycosylated cytokine conjugates |
| JPH0686375B2 (ja) * | 1989-09-25 | 1994-11-02 | 大塚製薬株式会社 | リポソーム製剤 |
| CA2090105A1 (en) * | 1990-08-29 | 1992-03-01 | Jean-Paul Soulillou | Protein polyligands joined to a stable protein core |
| US5159079A (en) * | 1991-12-20 | 1992-10-27 | Eli Lilly And Company | 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids |
| US5650398A (en) * | 1992-07-02 | 1997-07-22 | Cambridge Biotech Corporation | Drug delivery enhancement via modified saponins |
| US5273965A (en) * | 1992-07-02 | 1993-12-28 | Cambridge Biotech Corporation | Methods for enhancing drug delivery with modified saponins |
| EP0609606B1 (de) * | 1992-10-01 | 1996-12-11 | The Wellcome Foundation Limited | Tucaresol als Mittel zur Immunopotentierung |
| US5747024A (en) * | 1993-03-08 | 1998-05-05 | Immunex Corporation | Vaccine adjuvant comprising interleukin-15 |
| CA2157758A1 (en) * | 1993-03-19 | 1994-09-29 | Louis Chedid | Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokine |
| US5417982A (en) * | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
| US5547668A (en) * | 1995-05-05 | 1996-08-20 | The Board Of Trustees Of The University Of Illinois | Conjugates of folate anti-effector cell antibodies |
| US5602171A (en) * | 1995-06-07 | 1997-02-11 | Sugen Inc. | Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof |
| US6509313B1 (en) * | 1996-02-28 | 2003-01-21 | Cornell Research Foundation, Inc. | Stimulation of immune response with low doses of cytokines |
| ATE255910T1 (de) * | 1996-04-10 | 2003-12-15 | Sangstat Medical Corp | Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren |
| CA2253823A1 (en) * | 1996-05-06 | 1997-11-13 | Brigham And Women's Hospital | 5-lipoxygenase gene polymorphisms and their use in classifying patients |
| US6231859B1 (en) * | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
| WO1998052573A1 (en) * | 1997-05-20 | 1998-11-26 | Galenica Pharmaceuticals, Inc. | Triterpene saponin analogs having adjuvant and immunostimulatory activity |
| US6080725A (en) * | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| AU1095799A (en) * | 1997-10-17 | 1999-05-10 | Philip L. Fuchs | Folic acid derivatives |
| WO1999041613A1 (en) * | 1998-02-12 | 1999-08-19 | Immunivest | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
| WO2000009075A2 (en) * | 1998-08-14 | 2000-02-24 | Galenica Pharmaceuticals, Inc. | Chemically modified saponins and the use thereof as adjuvants |
| US6960449B2 (en) * | 1999-02-10 | 2005-11-01 | Cell Works Diagnostics, Inc. | Class characterization of circulating cancer cells isolated from body fluids and methods of use |
| AUPQ014699A0 (en) * | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using nanoparticles |
| AUPQ014799A0 (en) * | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
| AUPQ071299A0 (en) * | 1999-06-02 | 1999-06-24 | Access Pharmaceuticals Australia Pty Limited | Vitamin directed dual targeting therapy |
| JP4948728B2 (ja) * | 1999-08-17 | 2012-06-06 | パーデュー・リサーチ・ファウンデーション | 癌診断用抗体 |
| WO2001012172A1 (en) * | 1999-08-17 | 2001-02-22 | Purdue Research Foundation | Treatment of metastatic disease |
| WO2001022972A2 (en) * | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
| WO2001022990A2 (en) * | 1999-09-27 | 2001-04-05 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| US20020039583A1 (en) * | 1999-09-30 | 2002-04-04 | Subjeck John R. | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| JP2003527352A (ja) * | 2000-01-13 | 2003-09-16 | アンティジェニクス インコーポレーテッド | Ｃｐｇおよびサポニンの自然免疫刺激化合物、ならびにそれらの方法 |
| SK288201B6 (sk) * | 2000-03-31 | 2014-06-03 | Purdue Research Foundation | Farmaceutický prostriedok |
| EP1496934A4 (de) * | 2002-04-19 | 2006-08-02 | Endocyte Inc | Adjuvante verbesserte immunotherapie |
| EP1592457B1 (de) * | 2003-01-27 | 2012-07-25 | Endocyte, Inc. | Folat-vinblastin konjugat als arzneimittel |
| US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
-
2002
- 2002-09-26 AT AT02789173T patent/ATE451935T1/de not_active IP Right Cessation
- 2002-09-26 EP EP09179343A patent/EP2168598A1/de not_active Withdrawn
- 2002-09-26 JP JP2003531970A patent/JP2005523878A/ja active Pending
- 2002-09-26 WO PCT/US2002/030546 patent/WO2003028634A2/en active Application Filing
- 2002-09-26 EP EP02789173A patent/EP1434603B1/de not_active Expired - Lifetime
- 2002-09-26 DK DK02789173.8T patent/DK1434603T3/da active
- 2002-09-26 DE DE60234782T patent/DE60234782D1/de not_active Expired - Lifetime
- 2002-09-26 ES ES02789173T patent/ES2338305T3/es not_active Expired - Lifetime
- 2002-09-26 CA CA002461877A patent/CA2461877A1/en not_active Abandoned
- 2002-09-26 KR KR10-2004-7004233A patent/KR20040053136A/ko not_active Application Discontinuation
- 2002-09-27 US US10/259,006 patent/US20030086900A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003028634A3 (en) | 2003-10-16 |
| EP1434603A2 (de) | 2004-07-07 |
| CA2461877A1 (en) | 2003-04-10 |
| DK1434603T3 (da) | 2010-04-26 |
| JP2005523878A (ja) | 2005-08-11 |
| KR20040053136A (ko) | 2004-06-23 |
| US20030086900A1 (en) | 2003-05-08 |
| EP2168598A1 (de) | 2010-03-31 |
| WO2003028634A8 (en) | 2004-07-29 |
| WO2003028634A2 (en) | 2003-04-10 |
| EP1434603A4 (de) | 2005-11-30 |
| EP1434603B1 (de) | 2009-12-16 |
| DE60234782D1 (de) | 2010-01-28 |
| ES2338305T3 (es) | 2010-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE451935T1 (de) | Behandlungsverfahren mit liganden- immunogenkonjugaten | |
| BR0109704A (pt) | Método de tratamento usando conjugados de imunógeno ligando | |
| PT740650E (pt) | Co-farmacos como um metodo de administracao controlada de farmacos | |
| PT651646E (pt) | Conjugados terapeuticos de toxinas e farmacos | |
| EA200501810A1 (ru) | Композиция конъюгированного лекарственного средства | |
| EA200601761A1 (ru) | Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения | |
| CY1111814T1 (el) | Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων | |
| PT1135166E (pt) | Conjugados de hapteno-veiculo para o tratamento e prevencao da dependencia a nicotina | |
| BR9711580A (pt) | Conjugados hapteno-veìculo para uso em terapia contra uso indiscriminado de drogas e métodos para preparação destes | |
| TR200202231T2 (tr) | Amiloidojenik hastalığın önlenmesi ve tedavisi | |
| LU92133I2 (fr) | Brentuximab védotine ou ses sels pharmaceutiquement acceptables | |
| DE602004027888D1 (de) | Anti-cd70 antikörper-arzneimittelkonjugate und ihr | |
| FI953529A0 (fi) | Rokotteita, jotka sisältävät gangliosidi-KLH-konjugaattia ja QS-21-ainetta | |
| BR8905657A (pt) | Processo para preparar um quelante bifuncional,processo para preparar um complexo de um composto,processo para preparar um conjugado e processo para preparar uma formulacao farmaceutica | |
| DE60137146D1 (de) | Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten | |
| DK1276501T3 (da) | Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi | |
| ATE442856T1 (de) | Immunmodulatorische konstruktionen und ihre verwendung | |
| DK1377320T3 (da) | Polynukleotidbindingskomplekser omfattende steroler og saponiner | |
| ATE310750T1 (de) | Verotoxin b untereinheit zur immunisierunug | |
| DK1399186T3 (da) | Lægemiddel til behandling af tumorer og disses metastaser under anvendelse af et bindemolekyle mod knogle-sialoprotein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |